Clinical Trials with Cytokine-Induced Killer Cells and CAR-T Cell Transplantation for Non-small Cell Lung Cancer Treatme
The idea of utilizing the human immune system to eradicate tumors has been successfully practiced for the past decades, as reported in multiple published studies. Among cancer types, non-small cell lung cancer (NSCLC) is considered the most lethal type, l
- PDF / 291,886 Bytes
- 18 Pages / 504.567 x 720 pts Page_size
- 84 Downloads / 195 Views
Clinical Trials with Cytokine-Induced Killer Cells and CAR-T Cell Transplantation for Non-small Cell Lung Cancer Treatment Le Van Manh Hung, Hieu Trong Ngo, and Phuc Van Pham Abstract
The idea of utilizing the human immune system to eradicate tumors has been successfully practiced for the past decades, as reported in multiple published studies. Among cancer types, non-small cell lung cancer (NSCLC) is considered the most lethal type, leading to the necessity of finding an effective treatment for this category of cancer. Building on the success of basic and preclinical studies, numerous clinical trials of cytokine-induced killer (CIK) cells or chimera antigen receptor (CAR) T
Authors Hung Van-Manh Le and Hieu Trong Ngo have equally contributed to this chapter. L. V. M. Hung and H. T. Ngo Stem Cell Institute, University of Science, Ho Chi Minh City, Viet Nam e-mail: [email protected]; [email protected] P. Van Pham (*) Stem Cell Institute, University of Science, Ho Chi Minh City, Viet Nam Viet Nam National University Ho Chi Minh City, Ho Chi Minh City, Viet Nam Laboratory of Stem Cell Research and Application, University of Science, Ho Chi Minh City, Viet Nam Laboratory of Cancer Research, University of Science, Ho Chi Minh City, Viet Nam e-mail: [email protected]; [email protected]
cells for NSCLC therapy have been reported. In this review paper, we will summarize those findings in the context of clinical outcomes and adverse effects. In NSCLC, compared to CAR-T cells, CIK cells show relatively stronger antitumor efficacy and lower adverse effects. More clinical studies are needed to further confirm the clinical efficiency of both types of cellular immunotherapy. Keywords
CAR-T cells · Cytokine induced killer cells · Immune cell therapy · Non-small cell lung cancer
Abbreviations ACT CAR CIK CRS IL MHC-I NSCLC PD-1 TAAs TCR
Adoptive cell therapy Chimera antigen receptor Cytokine-induced killer Cytokine release syndrome Interleukin Major histocompatibility complex class I Non-small cell lung cancer Programmed cell death protein 1 Tumor-associated antigens T cell receptor
L. V. M. Hung et al.
1
Introduction
Lung cancer remains the most common type of cancer and the leading cause of cancer-related deaths worldwide, with approximately 2 million newly diagnosed cases (11.6% of total cases) and more than 1.7 million deaths (18.4% of total cases) (Bray et al. 2018). Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases (Molina et al. 2008). The survival rate of patients with earlyonset NSCLC can be relatively high after surgery (Knight et al. 2017). However, at the time of diagnosis, most patients already exhibit disease progression, and the median survival rate is only about 18 months after diagnosis (Wang et al. 2010). Despite early discovery and development of standard therapies, the treatment of NSCLC remains inefficient, partly due to both intrinsic resistance of lung cancer cells themselves and acquired resistance by continual administration of chemotherapeutic agents (Sh
Data Loading...
